Clinical Guest Contributors

51. How One Biopharma Company Overcame Trial Failure 10/6/2025

    PolyPid's Eyal Shoshani highlights the company's second attempt at its SHIELD trial, including things they did to revamp the trial design and the impact of AI in this and future trials.

52. How Government Shutdowns Set Back Clinical Trials 10/3/2025

    When the federal government shuts down, clinical research suffers. Empactful Ventures' Denise N. Bronner, Ph.D., explains the wide-reaching ramifications.

53. What Really Drives Recruitment, Enrollment, And Retention — According To A PI 10/3/2025

    Principal investigator Dr. Luke Twelves details some of his most trying and most successful patient recruitment experiences.

54. Maintaining Trust Between Clinical Researchers And Communities Requires Commitment & Candor 10/3/2025

    FasterCure leaders Amanda Wagner Gee, Lisa Lewis, and Esther Krofah contend that to maintain and build trust with communities, particularly those of need, more commitment and greater candor are needed.

55. Safety And Pharmacokinetics In LMIC Clinical Trials 10/2/2025

    Adequately profiling the safety and PK of a promising new drug is crucial. To conduct trials in low- and middle-income countries (LMICs), keep these considerations in mind.

56. Merck Maintains Human Touch In AI-Assisted Patient Recruitment And Education 10/2/2025

    SVP and Head of Global Clinical Trial Operations Jen Sheller shares how Merck’s “Zero Gravity” program and human-enabled AI are streamlining clinical research while honoring the human insights essential for trial success. 

57. FDA Pharma Advertising Crackdown Reshapes Clinical Research, Too 10/1/2025

    Empactul Ventures' Denise N. Bronner, Ph.D., explores how the FDA's crackdown on pharmaceutical advertising might affect clinical research patient recruitment and engagement.

58. Proximity To Patients Helps Unicycive Reduce Pill Burden 10/1/2025

    Unicycive CEO Shalabh Gupta, MD, shares how the company integrates patient feedback into the design of its trials, thus reducing pill burden.

59. Age Diversity In Clinical Trials: Considerations For Improving Older Adult Representation 9/30/2025

    Without prioritizing age diversity in recruitment and enrollment, research findings aren’t fully generalizable to this key demographic, limiting the applicability of trials. Let's look at what drug sponsors can do.

60. Pediatric Clinical Trials Must Approach Research With Today's And Tomorrow's Kids In Mind 9/30/2025

    Phoenix Children’s SVP of Research Stewart Goldman, MD, describes their patient-centric approach, offering insights into patient selection and education, as well as trial design.